The -7 chromosomal abnormalities with signs of myelodysplasia in chronic myeloid leukemia as a major red signal.
作者信息
Cayssials Emilie, Guilhot François
机构信息
Inserm CIC 1402, University Hospital of Poitiers, CHU de Poitiers, France.
出版信息
Haematologica. 2019 Jun;104(6):1096-1098. doi: 10.3324/haematol.2019.217034.
Abstract
摘要
相似文献
1
The -7 chromosomal abnormalities with signs of myelodysplasia in chronic myeloid leukemia as a major red signal.慢性髓性白血病中伴有骨髓发育异常迹象的-7染色体异常作为一个主要红色信号。
Haematologica. 2019 Jun;104(6):1096-1098. doi: 10.3324/haematol.2019.217034.
2
Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia.费城染色体阴性中期染色体 7 克隆异常预后不良及慢性髓性白血病潜在骨髓增生异常特征的相关性。
Haematologica. 2019 Jun;104(6):1150-1155. doi: 10.3324/haematol.2018.208801. Epub 2018 Dec 20.
3
[Role of chromosome aberrations in the development of leukemic process].[染色体畸变在白血病发生过程中的作用]
Vestn Akad Med Nauk SSSR. 1990(9):7-10.
4
Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.伊马替尼治疗费城染色体阳性慢性髓性白血病期间费城染色体阴性细胞中克隆性染色体异常的34例患者报告
Leukemia. 2004 Aug;18(8):1340-6. doi: 10.1038/sj.leu.2403399.
5
6
[Prognosis of clonal chromosomal abnormalities in Philadelphia negative metaphases cells in chronic myeloid leukemia with tyrosine kinase inhibitor therapy].[酪氨酸激酶抑制剂治疗慢性髓性白血病中费城阴性中期细胞克隆性染色体异常的预后]
Zhonghua Xue Ye Xue Za Zhi. 2019 Mar 14;40(3):209-214. doi: 10.3760/cma.j.issn.0253-2727.2019.03.009.
7
8
Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.附加染色体异常和 BCR-ABL 激酶结构域突变对费城染色体阳性慢性髓性白血病患者接受尼罗替尼治疗反应的影响。
Haematologica. 2010 Apr;95(4):582-8. doi: 10.3324/haematol.2009.014712. Epub 2009 Dec 16.
9
Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.在慢性期费城染色体阳性慢性髓性白血病患者接受甲磺酸伊马替尼治疗期间出现的费城染色体阴性中期的染色体异常。
Cancer. 2003 Nov 1;98(9):1905-11. doi: 10.1002/cncr.11729.
10
Duplication of chromosome 9 carrying a BCR/ABL chimeric gene in Philadelphia chromosome negative chronic myeloid leukemia.9号染色体重复，在费城染色体阴性慢性髓性白血病中携带BCR/ABL嵌合基因。
Cancer Genet Cytogenet. 1996 Jul 15;89(2):166-9. doi: 10.1016/0165-4608(96)00039-8.
引用本文的文献
1
NK cell-based immunotherapy strategies for myeloid leukemia.基于自然杀伤细胞的髓系白血病免疫治疗策略
Front Immunol. 2025 Jul 14;16:1621885. doi: 10.3389/fimmu.2025.1621885. eCollection 2025.
本文引用的文献
1
Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia.费城染色体阴性中期染色体 7 克隆异常预后不良及慢性髓性白血病潜在骨髓增生异常特征的相关性。
Haematologica. 2019 Jun;104(6):1150-1155. doi: 10.3324/haematol.2018.208801. Epub 2018 Dec 20.
2
Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology.慢性髓性白血病临床实践指南（2019 年版），NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2018 Sep;16(9):1108-1135. doi: 10.6004/jnccn.2018.0071.
3
Clonal chromosomal aberrations in Philadelphia negative cells such as monosomy 7 and trisomy 8 may persist for years with no impact on the long term outcome in patients with chronic myeloid leukemia.费城阴性细胞中的克隆性染色体畸变，如7号染色体单体和8号染色体三体，可能会持续数年，而对慢性髓性白血病患者的长期预后没有影响。
Cancer Genet. 2017 Oct;216-217:1-9. doi: 10.1016/j.cancergen.2017.04.066. Epub 2017 Apr 28.
4
Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment.慢性粒细胞白血病治疗期间出现在费城染色体阴性中期的克隆性染色体异常。
Blood. 2017 Nov 9;130(19):2084-2091. doi: 10.1182/blood-2017-07-792143. Epub 2017 Aug 23.
5
Cytogenetics in CML: more important than you think.慢性粒细胞白血病的细胞遗传学：比你想象的更重要。
Blood. 2016 Jun 2;127(22):2661-2. doi: 10.1182/blood-2016-04-708206.
6
Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.酪氨酸激酶抑制剂治疗时代慢性髓性白血病染色体异常的风险分层
Blood. 2016 Jun 2;127(22):2742-50. doi: 10.1182/blood-2016-01-690230. Epub 2016 Mar 22.
7
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.欧洲白血病网络关于慢性髓性白血病管理的建议：2013 年版。
Blood. 2013 Aug 8;122(6):872-84. doi: 10.1182/blood-2013-05-501569. Epub 2013 Jun 26.
8
Myelodysplastic syndrome with Ph negative monosomy 7 chromosome following transient bone marrow dysplasia during imatinib treatment for chronic myeloid leukemia.慢性髓性白血病伊马替尼治疗期间短暂性骨髓发育异常后出现的伴有Ph阴性7号染色体单体的骨髓增生异常综合征
Intern Med. 2011;50(5):481-5. doi: 10.2169/internalmedicine.50.4481. Epub 2011 Mar 1.
9
Factors influencing a second myeloid malignancy in patients with Philadelphia-negative -7 or del(7q) clones during tyrosine kinase inhibitor therapy for chronic myeloid leukemia.慢性髓性白血病患者在酪氨酸激酶抑制剂治疗期间，费城染色体阴性 -7 或 del(7q) 克隆影响二次髓系恶性肿瘤发生的相关因素
Cancer Genet. 2011 Jan;204(1):39-44. doi: 10.1016/j.cancergencyto.2010.08.017.
10
Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST.一名胃肠间质瘤患者在甲磺酸伊马替尼治疗期间出现骨髓增生异常综合征。
Leuk Res. 2009 Sep;33(9):e143-4. doi: 10.1016/j.leukres.2009.04.012. Epub 2009 May 13.
Zotero 插件